Patients are at the heart of everything we do at Aspen Neuroscience.
We are committed to supporting people living with Parkinson’s disease, their families and their care partners. This is what drives our commitment to developing personalized cell therapies designed to address the underlying biology of the disease with the goal of helping patients to continue, as much as they can, the life they have always enjoyed.
Parkinson’s disease (PD) is a progressive neurodegenerative disorder defined by the loss of dopaminergic neurons in the brain, resulting in characteristic motor symptoms, along with a range of non-motor symptoms. Over the last several decades, there has been limited improvement in the standard of care, even as more people are affected by this progressive disease.
To address these challenges, Aspen is developing sasineprocel, an investigational, single-dose, personalized (autologous) cell therapy for Parkinson’s disease.
Sasineprocel is designed to replace the dopamine-producing neurons and the underlying neural circuitry lost as the disease progresses. As a personalized cell therapy, sasineprocel is created from a patient’s own cells, removing the need for immunosuppression which is required for donor-derived or allogeneic cell therapies. The procedure only occurs once, and no hardware is implanted.
With this approach, our goal is to restore dopamine signaling and rebuild neural connections that may support motor and non-motor function and quality of life.
Sasineprocel is created from a patient’s own cells, collected through a small skin biopsy (the size of a pencil eraser top). These cells are then reprogrammed into stem cells (called induced pluripotent stem cells or iPSCs) which “turn back the cells’ biological clock” to a pre-diseased state, creating a “blank canvas” from which to develop the potential therapy. In this case, they are then differentiated into the cells that can trigger dopamine production (dopaminergic precursor cells or DANPCs) and potentially help to rebuild the underlying neural circuitry of the brain. The personalized cell composition is delivered through image-guided administration to the putamen, the area of the brain where restoration of dopamine signaling is needed.
Sasineprocel has received Regenerative Medicine Advanced Therapy and Fast Track designations from the U.S. Food and Drug Administration. It remains investigational and has not been approved by the FDA.
Please direct all inquiries related to sasineprocel (ANPD001) active clinical studies as follows:
+1 (800) 792-1015
Monday through Friday, 8:00 AM to 9:00 PM ET
For all other inquiries, please visit our general contact page.
This takes you to the Clinical Research Organization managing clinical trials on Aspen’s behalf. They will answer questions about any ongoing studies. Aspen does not see these inquiries and does not assess or determine individual eligibility for clinical trials. Eligibility and enrollment decisions are made by participating clinical trial sites in accordance with the study protocol and under the direction of the site’s Principal Investigator. Aspen Neuroscience does not determine individual eligibility for clinical trials. All trial-related enrollment and eligibility decisions are made by participating clinical trial sites in accordance with the study protocol and under the direction of the site Principal Investigator. Sasineprocel (ANPD001) is investigational and has not been approved by the U.S. Food and Drug Administration. Aspen Neuroscience does not currently offer or participate in compassionate use or expanded access programs for sasineprocel (ANPD001).
